Table of Contents

Relevance tier by entity

Entity Tier Description
BL 2 Role of CDC27 mutations in BL requires confirmation

Mutation incidence in large patient cohorts (GAMBL reanalysis)

DLBCL

Entity Collection N mutated Incidence 95% CI
DLBCL GAMBL without Reddy 1,089 8 0.0073 [0.0023,0.0124]
DLBCL GAMBL with Reddy 2,088 14 0.0067 [0.0032,0.0102]
DLBCL BC 231 2 0.0087 [0,0.0206]
DLBCL Dana-Farber 303 2 0.0066 [0,0.0157]
DLBCL NCI 470 4 0.0085 [2e-04,0.0168]
DLBCL Reddy 999 6 0.0060 [0.0012,0.0108]
DLBCL DLBCL_ICGC 85 0 0.0012 [0,0.0085]

FL

Failed to render page: conflicting chdir during another chdir block

BL

Failed to render page: conflicting chdir during another chdir block

Mutation pattern and selective pressure estimates

Failed to render page: conflicting chdir during another chdir block

Failed to render page: conflicting chdir during another chdir block

References

1.
Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, Showell J, Ghosh S, Street L, Davidson M, Carey C, Tobin J, Perumal D, Vose JM, Lunning MA, Sohani AR, Chen BJ, Buckley S, Nastoupil LJ, Davis RE, Westin JR, Fowler NH, Parekh S, Gandhi M, Neelapu S, Stewart D, Bhalla K, Iqbal J, Greiner T, Rodig SJ, Mansoor A, Green MR. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica. 2022 Mar;107(3):690–701. PMCID: PMC8883549

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.